Welcome to our dedicated page for ASAHI KAISEI CRP UNSP/ADR news (Ticker: AHKSY), a resource for investors and traders seeking the latest updates and insights on ASAHI KAISEI CRP UNSP/ADR stock.
Asahi Kasei Corporation (symbol: AHKSY) is a diversified Japanese technology and manufacturing company dedicated to contributing to life and living globally. Since its foundation in 1922 with ammonia and cellulose fiber businesses, Asahi Kasei has continuously transformed its business portfolio to meet evolving market demands. The company operates through three primary sectors: Material, Homes, and Health Care.
In the Material sector, Asahi Kasei produces a wide array of products, including battery separators, biodegradable textiles, engineering plastics, and sound solutions. Recently, the company announced a significant investment in an integrated plant in Ontario, Canada, for manufacturing Hipore™ wet-process lithium-ion battery separators, in partnership with Honda and the Development Bank of Japan.
In the Health Care sector, Asahi Kasei focuses on devices and systems for acute critical care, dialysis, therapeutic apheresis, and the manufacturing of biotherapeutics. The company recently completed the construction of its third assembly plant for Planova™ virus removal filters in Japan and announced the launch of a new plasmid DNA manufacturing facility in Texas, USA, through its subsidiary, Bionova Scientific.
Asahi Kasei is also making strides in the renewable energy sector with its hydrogen business. The company celebrated the opening of a new hydrogen pilot plant in Kawasaki, Japan, marking a significant milestone toward commercializing large-scale alkaline water electrolysis systems for green hydrogen production.
In addition to these advancements, Asahi Kasei is committed to sustainability, aiming to reach carbon neutrality by 2050. The company's R&D initiatives include the development of high ionic conductive electrolytes for lithium-ion batteries, which promise enhanced performance and durability at extreme temperatures.
Asahi Kasei's recent partnership with Axolabs to establish a cutting-edge oligonucleotide cGMP manufacturing facility in Berlin underscores its commitment to innovation in the biopharmaceutical industry. This collaboration aims to accelerate the development and commercialization of oligonucleotide-based therapies to improve patient quality of life globally.
With over 48,000 employees worldwide, Asahi Kasei continues to be a global leader in providing innovative solutions to the world's challenges, ensuring sustainable growth and development.
Asahi Kasei will unveil its AKXY2 concept car at K 2022 in Düsseldorf, Germany, from October 19-26. This model showcases the company's advanced technology and sustainable materials, including innovative particle foams and bio-based fillers aimed at electric vehicles. Key materials on display include polycarbonates produced using CO2 as a raw material and premium microfiber Dinamica®. The AKXY2 also features cellulose-based materials and next-gen engineering plastics. Asahi Kasei emphasizes its commitment to sustainability and innovation across its diverse product portfolio.
Asahi Kasei Bioprocess America will showcase its MOTIV™ Buffer Management Technology at ACHEMA 2022 in Frankfurt, scheduled from August 22-26, 2022. This innovative system blends buffers from concentrates in small, single-use bags, significantly enhancing efficiency and precision in pharmaceutical production. It has received multiple accolades, including ‘Best in Show’ at Interphex 2017 and ‘Technology of the Decade’ from Bioprocess International in 2012. The system supports rapid and sustainable pharmaceutical manufacturing, allowing medicines to reach patients globally faster.
Asahi Kasei has developed a new system for calculating the carbon footprint (CFP) of its synthetic rubber and elastomers products, which will start providing data to customers from June 2022. The system utilizes the DEEP group-wide management infrastructure for enhanced CFP visualization and reduction strategies. Asahi Kasei aims for carbon neutrality by 2050, incorporating sustainable practices like using butadiene derived from plastic waste. This system is crucial as regulations on carbon footprints increase, and it tailors data to meet customer requirements.
Asahi Kasei has developed a new platform in collaboration with NTT DATA to monitor greenhouse gas (GHG) emissions and calculate carbon footprints for its performance plastics used in various industries. This initiative, part of its sustainability efforts, began in April 2022, with customer data sharing starting in May 2022. The platform aims to provide detailed insights into GHG emissions across the supply chain, enhancing accountability and supporting decarbonization. Asahi Kasei remains committed to achieving carbon neutrality by 2050.
Asahi Kasei Medical announced on April 14, 2022, the acquisition of Bionova Scientific, LLC, specializing in biopharmaceutical contract development and manufacturing. This strategic move enhances Asahi Kasei's bioprocess business, allowing it to offer advanced manufacturing capabilities for next-generation antibody drugs. Bionova's GMP-compliant facility and expertise in complex biopharmaceuticals are set to meet increasing market demand. The acquisition is pending necessary regulatory approvals.
Asahi Kasei will showcase its AKXY Pod automotive interior prototype at the SAE World Congress Experience in Detroit from April 5-7, 2022. The presentation includes advancements in keeping vehicle cabins safe from pathogens using Crystal IS's Klaran UVC LEDs. The Healthy Car Portfolio emphasizes safety through technologies like touch-free alcohol sensors and innovative textiles. The event will highlight solutions for enhancing comfort and cleanliness in vehicles while addressing post-COVID-19 market needs, emphasizing the importance of healthy automotive innovations.
Asahi Kasei has announced a strategic partnership with Genomatica to develop biomass-derived hexamethylenediamine (HMD), enhancing the production of sustainable polyamide 66 (Leona™). This collaboration allows Asahi Kasei to evaluate bio-HMD as a feedstock, aiming to be first-to-market in sustainable engineering plastics for automotive and electronics. Asahi Kasei targets carbon neutrality by 2050, with bio-HMD potentially reducing greenhouse gas emissions. The partnership aligns with increasing global demand for eco-friendly materials in manufacturing.
Asahi Kasei Medical plans to expand its production capacity for Planova™ filters by constructing a new assembly plant in Nobeoka, Miyazaki, Japan. This facility aims to enhance manufacturing automation and efficiency, with construction set to begin in Q3 2022 and completion expected in early 2024. The demand for Planova™ filters has surged due to the COVID-19 pandemic's impact on the biotherapeutics market. Asahi Kasei Medical has been investing in production capacity to meet this demand, reinforcing its position as a market leader in virus filtration.
FAQ
What is the current stock price of ASAHI KAISEI CRP UNSP/ADR (AHKSY)?
What is the market cap of ASAHI KAISEI CRP UNSP/ADR (AHKSY)?
What sectors does Asahi Kasei operate in?
What recent projects has Asahi Kasei announced?
What is Asahi Kasei's commitment to sustainability?
Who are Asahi Kasei's key partners in recent ventures?
What are Asahi Kasei's contributions to the biopharmaceutical industry?
Where is Asahi Kasei's new hydrogen pilot plant located?
What is the Hipore™ wet-process separator used for?
How does Asahi Kasei support innovation in manufacturing?
What are the benefits of Asahi Kasei's high ionic conductive electrolyte?
How many employees does Asahi Kasei have globally?
